HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $283 to $272.
HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $272
HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $283 to $272.
Related Posts
Credit Suisse Maintains Outperform Rating for Brookfield Renewable: Here’s What You Need To Know
Credit Suisse has decided to maintain its Outperform rating of Brookfield Renewable (NYSE:BEP) and raise its price target…
CZ’s Next Big Move? Binance.US Appoints Former PayPal Exec As CFO
Binance.US (CRYPTO: BNB) has appointed Jasmine Lee, ex-Paypal (NASDAQ: PYPL) Holdings executive, as its Chief Financial Officer.
China Semiconductor Fallout: After Texas Instruments Issues Weak Forward Guidance, Will KLA Corp Do The Same?
Concerns that rival KLA Corp. (NASDAQ: KLAC) will provide weak guidance as the semiconductor industry battles new regulations in China and other challenges have been stoked by Texas Instruments Incorporated's (NASDAQ: